1. Basic Information
Disease Overview
- Rabies: Viral encephalitis transmitted through bites or scratches from infected mammals (dogs cause the large majority of the >59,000 estimated annual deaths worldwide, mostly in Asia and Africa; bats are the primary vector in the U.S.). Once clinical symptoms appear, rabies is nearly 100% fatal — it is one of the most lethal infectious diseases known, but is also nearly 100% preventable with timely prophylaxis.
Pre- and Post-Exposure Regimens
| Regimen | Who | Schedule |
|---|---|---|
| Pre-exposure prophylaxis (PrEP) | Travelers to high-risk areas, veterinarians, animal handlers, lab workers, spelunkers | 2-dose series (days 0, 7) per 2022 ACIP update, reduced from the older 3-dose series for most people; occupational-risk groups undergo periodic titer checks and booster as needed |
| Post-exposure prophylaxis (PEP), previously unvaccinated | Anyone with a bite/scratch/mucous-membrane exposure to a potentially rabid animal | 4-dose vaccine series (days 0, 3, 7, 14; 5th dose on day 28 if immunocompromised) plus rabies immune globulin (RIG) infiltrated at the wound site |
| PEP, previously vaccinated (PrEP or prior PEP) | Same as above, with documented prior vaccination | 2-dose booster series (days 0, 3); no RIG needed |
Source: CDC ACIP Rabies Recommendations (2022 update); WHO Rabies position paper (2018).
Licensed Products (U.S.)
- Imovax Rabies® (Sanofi) — human diploid cell vaccine (HDCV).
- RabAvert® (GSK) — purified chick embryo cell vaccine (PCECV).
- Rabies immune globulin (HyperRAB, Imogam Rabies-HT) — provides immediate passive antibody at the wound site while active immunity develops from the vaccine series.
2. Pre-Licensure Clinical Trial Data
Because deliberately exposing trial participants to rabies would be unethical, efficacy cannot be studied via placebo-controlled challenge trials in humans. Evidence instead comes from immunogenicity trials, and from the extensive real-world record of PEP outcomes.
| Metric | Data | Evidence Strength |
|---|---|---|
| Seroconversion (adequate neutralizing antibody titer) | >95–99% after complete PrEP or PEP series in immunogenicity trials | Strong |
| 2-dose vs. 3-dose PrEP non-inferiority (2022 ACIP change) | Multiple immunogenicity studies supported the shift to a 2-dose primary PrEP series for most people | Strong |
| Direct PEP effectiveness | No RCTs (unethical); real-world record across millions of PEP courses shows treatment failures are exceedingly rare and almost always tied to delayed/incomplete PEP or omission of RIG | Strong |
Key Limitations
- No placebo-controlled human efficacy trial: Ethically impossible; effectiveness is inferred from immunogenicity and the real-world PEP failure-case literature.
- PEP failures, when they occur, are almost always attributable to protocol deviations (delayed treatment initiation, RIG omitted or not infiltrated at the wound, incomplete dose series) rather than vaccine failure per se.
3. Post-Licensure Safety Data
Post-Licensure Safety Monitoring
| Metric | Finding |
|---|---|
| Serum sickness-like reactions with booster doses | Reported in up to ~6% of people receiving multiple HDCV boosters, thought to be an immune-complex reaction to the human albumin stabilizer; more common with older vaccine lots and repeat boosting than with primary series |
| Historical GBS-like reactions with older nerve-tissue vaccines | Older Semple-type (nerve-tissue-derived) rabies vaccines, still used in some countries decades ago, carried a much higher neurologic complication rate; modern cell-culture vaccines (HDCV, PCECV) do not share this risk profile |
| VAERS review, modern cell-culture vaccines | Dominated by injection site and mild systemic reactions; no unusual serious safety signal identified |
⚠ Critical Caveat
Rabies is essentially always fatal once symptomatic, and PEP is highly time-sensitive. Any potential rabies exposure warrants urgent medical evaluation regardless of prior vaccination status — do not wait for confirmatory animal testing where risk is significant.
4. Documented Adverse Events — Evidence of Association
▶ Strong Evidence of Causal Association
- Injection site pain, redness, swelling: Common, ~30–74% depending on vaccine/regimen. Self-limited. Strong
- Headache, dizziness, myalgia, nausea: ~5–40%. Self-limited. Strong
- Serum sickness-like reaction (booster doses): Up to ~6% with repeat HDCV boosting; immune-complex mediated, self-limited but can be uncomfortable (urticaria, arthralgia, fever, 2–21 days after boost). Strong
- Anaphylaxis: Rare, consistent with other injectable cell-culture vaccines. Strong
▶ Published Evidence Does Not Support a Causal Association
- Guillain-Barré syndrome, modern cell-culture vaccines: The elevated GBS-like signal was specific to older nerve-tissue-derived (Semple-type) vaccines; no consistent signal has been found with HDCV/PCECV. No Association (modern vaccines)
5. Disease Prevention Benefits
Effectiveness in Practice
| Metric | Data |
|---|---|
| PEP effectiveness when protocol followed correctly and promptly | Essentially 100%; documented human rabies deaths after correctly and promptly administered PEP (vaccine + RIG) are exceedingly rare case reports |
| Global mortality burden | ~59,000 deaths/year worldwide (WHO estimate), >95% in Asia and Africa, overwhelmingly linked to dog bites in areas with limited PEP access |
| U.S. burden | Typically 1–3 human deaths/year, almost always from unrecognized bat exposure without PEP; PEP is administered to tens of thousands of people annually in the U.S. as a precaution |
Source: WHO Rabies Fact Sheet; CDC Rabies Surveillance Summaries.
6. Evidence Summary
Modern cell-culture rabies vaccines, combined with rabies immune globulin for unvaccinated exposures, are considered essentially 100% effective at preventing a disease that is otherwise almost universally fatal once symptomatic. The main real-world "failures" reflect delayed or incomplete treatment rather than vaccine performance. Adverse events are generally mild, with serum sickness-like reactions to repeat boosters being the most distinctive, well-characterized reaction pattern.
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| PEP effectiveness (protocol followed) | Strong | Essentially 100% when given promptly and completely |
| PrEP immunogenicity | Strong | >95–99% seroconversion |
| Serum sickness-like reactions (repeat boosters) | Strong | Up to ~6% with repeat HDCV boosting |
| GBS (modern vaccines) | No Association | Signal specific to older nerve-tissue vaccines, not HDCV/PCECV |
7. Key References
- WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec. 2018;93(16):201–219.
- CDC. Use of a Modified Preexposure Prophylaxis Vaccination Schedule for Rabies. MMWR. 2022;71(18):619–627.
- CDC. Rabies. CDC Yellow Book, Travelers’ Health. cdc.gov/yellowbook
- Manning SE, et al. Human Rabies Prevention — ACIP Recommendations. MMWR Recomm Rep. 2008;57(RR-3):1–28.
- WHO. Rabies Fact Sheet. who.int